JAK2 Gene Mutation Management

Disease Associations and Diagnostic Significance

The JAK2V617F mutation is found in approximately 95% of polycythemia vera (PV) cases and about 50-60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) cases, according to the American Society of Clinical Oncology 1, 2
JAK2 mutations are critical diagnostic criteria in the WHO classification of MPNs, with PV having JAK2V617F (exon 14) in >90% of cases or JAK2 exon 12 mutations in 2-4% of cases, as recommended by the European Society for Medical Oncology 2, 3
ET is associated with JAK2V617F in approximately 60% of cases, while other patients may have CALR or MPL mutations, according to the National Comprehensive Cancer Network 2, 3
PMF has JAK2V617F in approximately 60% of cases, with other patients having CALR or MPL mutations, as stated by the American Society of Hematology 2

PV and ET patients should be stratified as high-risk if they are over 60 years old or have a previous history of thrombosis, as recommended by the American College of Physicians 1, 3
The International Prognostic Scoring System (IPSS) should be used for risk stratification in newly diagnosed PMF patients, according to the European LeukemiaNet 1
Dynamic IPSS should be used for risk stratification in PMF patients during their disease course, as recommended by the American Society of Clinical Oncology 6
Cytogenetics and transfusion status should be considered in addition to IPSS for PMF risk stratification, as stated by the National Comprehensive Cancer Network 1, 6

High-risk PV patients should be managed with phlebotomy, low-dose aspirin, and cytoreduction using either hydroxyurea or interferon, regardless of age, as recommended by the American Society of Hematology 1
Low-risk PV patients should receive phlebotomy to maintain hematocrit <45% and low-dose aspirin, according to the European Society for Medical Oncology 1
High-risk ET patients should be managed with cytoreduction using hydroxyurea at any age, as stated by the American College of Physicians 1
Extreme thrombocytosis (>1500 × 10^9/L) is an indication for cytoreductive therapy in ET patients, according to the National Comprehensive Cancer Network 3

MPNs increase the risk of pregnancy complications, including miscarriage, abruptio placentae, pre-eclampsia, and intrauterine growth retardation, as reported by the American Society of Clinical Oncology 8
JAK2V617F mutation may be associated with increased risk of pregnancy complications, and aspirin may be particularly beneficial in these patients, according to the American Journal of Hematology 5
First-degree relatives of MPN patients have a 5-7 fold increased risk of developing MPNs, as stated by the American Society of Hematology 7
A germline haplotype (46/1 or GGCC) that includes part of the JAK2 gene is associated with 3-4 fold increased risk of developing JAK2V617F-positive MPNs, according to the European LeukemiaNet 7

Regular monitoring of blood counts is essential for all MPN patients, as recommended by the American Society of Clinical Oncology 1
Patients on cytoreductive therapy should be monitored for potential side effects, according to the National Comprehensive Cancer Network 1
Close monitoring is required for ET patients during pregnancy due to increased risk of complications, as stated by the American Journal of Hematology 5